Michael Dao

A First‐in‐Patient, Multicenter, Double‐Blind, 2‐Arm, Placebo‐Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP‐499, in Chronic Kidney Disease

J. Neutel, Lijun Wu, L. Sabounjian, 2016, Clinical pharmacology in drug development.

LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial

Kenneth E. Homer, R. Loomba, J. Neutel, 2019, Journal of Hepatology.

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients

Roger Williams, M. Choi, R. D. de Knegt, 2017, Front. Immunol..